原发性胃非霍奇金淋巴瘤生存分析  

Survival analysis of primary gastric non-Hodgkin lymphoma

作　　者：韩利梅[1] 杨顺娥[2] 

机构地区：[1]新疆医科大学第二附属医院呼吸科 [2]新疆医科大学第三附属医院内三科,新疆830063

出　　处：《重庆医科大学学报》2011年第9期1119-1122,共4页Journal of Chongqing Medical University

摘　　要：目的:探讨51例原发性胃非霍奇金淋巴瘤(Primary gastric non-Hodgkin lymphoma,PGNHL)的临床特征,治疗及预后因素。方法:回顾性分析新疆医科大学附属肿瘤医院收治的51例PGNHL,采用单因素分析、多因素分析和Kaplan-Meier生存曲线分析评价该病的临床特征及预后因素。结果:51例患者中,黏膜相关淋巴组织淋巴瘤23例(45.1%),弥漫性大B细胞淋巴瘤17例(33.3%),淋巴浆细胞性淋巴瘤1例(2.0%),T细胞型淋巴瘤3例(5.9%),未能分型淋巴瘤7例(13.7%)。Ⅰ期和Ⅱ期患者34例(66.7%),Ⅲ期和Ⅳ期患者17例(33.3%)。全组随访病例5年生存率为47.1%。单因素分析显示,LDH≥240 U/L(P=0.001),临床分期≥Ⅲ期(P=0.002)I,PI预后指数≥3(P=0.002)的患者预后不佳。黏膜相关淋巴组织淋巴瘤较其它类型预后好(P=0.048)。多因素分析显示,LDH及临床分期为独立预后因素。结论:PGNHL的常见病理类型为黏膜相关淋巴组织淋巴瘤,预后较其它类型好,LDH水平增高提示预后差,治疗策略上应采用化疗为主的治疗模式。Objective：To investigate the prognosis factors,therapy and clinical manifestations of primary gastric non-Hodgkin lymphoma.Methods：The clinical and pathological data of 51 patients with primary gastric non-Hodgkin lymphoma were reviewed.The clinical data were analyzed by log-rank,COX and Kaplan-Meier method.Results：Histopathological types of 51 patients were classified into 23（45.1%） of mucosa-associated lymphoid tissue lymphoma,17（33.3%） of diffuse large B cell lymphoma,1（2.0%） of lymphoplasmacytic lymphoma,3（5.9%） of T cell type and 7（13.7%）of non-specific type,respectively.Thirty-four（66.7%） patients were in stage Ⅰand Ⅱ,and seventeen（33.3%） in stage Ⅲ and Ⅳ.The overall survival rates at 5 years was 47.1%.Univariate analysis showed that patients with LDH≥240 U/L（P=0.001）,clinical stage≥Ⅲ（P=0.002） and IPI score≥3（P=0.002） had poorer prognosis.Mucosa-associated lymphoid tissue lymphoma had richer than others.Multivariate analysis showed LDH was independent prognostic factor.Conclusion：The majority of primary gastric lymphoma is mucosa-associated lymphoid tissue lymphoma,and the prognosis is richer than others.Patients with LDH ≥240 U/L means the prognosis is poorer than other patients.Chemotherapy-dominated modality is recommended for patients with PGNHL.

关 键 词：非霍奇金淋巴瘤 胃 预后 因素分析 

分 类 号：R733.1[医药卫生—肿瘤]